COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry

[1]  J. Nattermann,et al.  First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)” , 2020, Infection.

[2]  C. Miething,et al.  Covid‐19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany , 2020, Cancer medicine.

[3]  H. Wildiers,et al.  Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis , 2020, ESMO Open.

[4]  E. Wulff-Burchfield,et al.  Sex-bias in COVID-19-associated illness severity and mortality in cancer patients: A systematic review and meta-analysis , 2020, EClinicalMedicine.

[5]  D. Kerr,et al.  COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study , 2020, The Lancet Oncology.

[6]  H. Einsele,et al.  Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. , 2020, Haematologica.

[7]  A. Sanyaolu,et al.  Comorbidity and its Impact on Patients with COVID-19 , 2020, SN Comprehensive Clinical Medicine.

[8]  N. Joharatnam-Hogan,et al.  COVID-19 cancer conundrum—evidence driving decisions or the lack of it? , 2020, BMC Medicine.

[9]  Zhiquan Hu,et al.  Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[10]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[11]  D. Kerr,et al.  COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.

[12]  S. Kalnicki,et al.  Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.

[13]  M. Santillana,et al.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[14]  R. Gale,et al.  COVID-19 in persons with haematological cancers , 2020, Leukemia.

[15]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[16]  C. Wang,et al.  Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.

[17]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[18]  H. Rothan,et al.  The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.

[19]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[20]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[21]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[22]  P. Ferdinande,et al.  The variability of critical care bed numbers in Europe , 2012, Intensive Care Medicine.